Real-time index price for Nasdaq Composite [TR] (XCMP), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

President of NYU College Republicans resigns after calling Barron Trump ‘an oddity’ ...

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, announces ...

Elon Musk’s artificial-intelligence company xAI unveiled an improved version of its Grok chatbot and the model that powers it ...

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $72 from $70 and keeps a Buy rating on the shares following the Q4 report.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nexalin Technology (NXL) has received Institutional Review Board – IRB – approval from the University of California, San Diego, or UCSD, for ...

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The San Diego-based company said it had net income of $1.06 per share. Earnings, adjusted for one-time gains and costs, came to $1.26 per share. The results exceeded Wall Street expectations.

Elon Musk’s artificial intelligence startup, xAI, released its updated Grok-3 model, which is a chatbot that competes with ...

Reports Q4 revenue $298.0M, consensus $285.7M. “I am excited to announce that the significant growth we achieved throughout the year culminated ...